Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Completed · Phase 2

Conditions studied: Mantle Cell Lymphoma, B Cell Lymphoma, Multiple Myeloma

In brief

This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.

Key facts

Study ID

NCT01148108

Run by

Telik

People needed

14

Starts

2010-06-01

Expected to finish

2012-09-01

Last updated by the study team

2013-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• relapsed or refractory disease
• histologically or cytologically confirmed disease
• characteristic immunophenotypic profiles
• measurable disease (for lymphoma patients)
• ECOG performance status of 0-2
• adequate liver and kidney function
• adequate bone marrow reserves
• ineligible or unwilling to undergo autologous stem cell transplantation

You may not qualify if…

• failure to recover from any major surgery within 4 weeks of study entry
• pregnant or lactating women
• women of child-bearing potential not using reliable and appropriate contraception
• routine prophylactic use of G-CSF required within 2 weeks of study entry
• Grade 3 or higher peripheral neuropathy
• history of hepatitis B virus or HIV
• central nervous system or meningeal involvement by lymphoma or multiple myeloma

Where it is running

• Cancer Institute of New Jersey — New Brunswick, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.